Autor: "Korman, Alan" - OpacWWW

Tytuł :: Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more.
Autorzy :: Turnis ME; Department of Immunology; St. Jude Children`s Research Hospital; Memphis, TN USA.
Korman AJ
Drake CG
Vignali DA; Pokaż więcej
Źródło :: Oncoimmunology [Oncoimmunology] 2012 Oct 01; Vol. 1 (7), pp. 1172-1174.
Typ publikacji :: Journal Article
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 24 24.

Tytuł :: In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice.
Autorzy :: Palmer BE; Division of Allergy and Clinical Immunology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. />Neff CP
Lecureux J
Ehler A
Dsouza M
Remling-Mulder L
Korman AJ
Fontenot AP
Akkina R; Pokaż więcej
Źródło :: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2013 Jan 01; Vol. 190 (1), pp. 211-9. Date of Electronic Publication: 2012 Dec 03.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :: CD4-Positive T-Lymphocytes/*immunology
CD4-Positive T-Lymphocytes/*virology
Down-Regulation/*immunology
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Programmed Cell Death 1 Receptor/*physiology
Viral Load/*immunology
Animals ; B7-H1 Antigen/immunology ; CD4 Lymphocyte Count ; CD4-Positive T-Lymphocytes/cytology ; HIV Infections/immunology ; HIV Infections/pathology ; HIV-1/growth & development ; HIV-1/immunology ; Humans ; Mice ; Mice, Inbred BALB C ; Mice, Knockout ; Programmed Cell Death 1 Receptor/biosynthesis ; Up-Regulation/immunology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 25 25.

Tytuł :: BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.
Autorzy :: Kuhne MR; Department of Cell Biology and Physiology, BDC, Bristol-Myers Squibb, Lawrenceville, New Jersey, USA.
Mulvey T
Belanger B
Chen S
Pan C
Chong C
Cao F
Niekro W
Kempe T
Henning KA
Cohen LJ
Korman AJ
Cardarelli PM; Pokaż więcej
Źródło :: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2013 Jan 15; Vol. 19 (2), pp. 357-66. Date of Electronic Publication: 2012 Dec 04.
Typ publikacji :: Journal Article
MeSH Terms :: Antibodies, Monoclonal/*pharmacology
Antibodies, Monoclonal, Humanized/*pharmacology
Antineoplastic Agents/*pharmacology
Apoptosis/*drug effects
Hematologic Neoplasms/*immunology
Receptors, CXCR4/*immunology
Animals ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Agents/administration & dosage ; Calcium/metabolism ; Cell Line, Tumor ; Chemokine CXCL12/immunology ; Chemokine CXCL12/metabolism ; Disease Models, Animal ; Hematologic Neoplasms/drug therapy ; Hematologic Neoplasms/pathology ; Humans ; Ligands ; Mice ; Receptors, CXCR4/antagonists & inhibitors ; Receptors, CXCR4/metabolism ; Tumor Burden/drug effects ; Xenograft Model Antitumor Assays
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 26 26.

Tytuł :: Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis.
Autorzy :: Chang KC
Burnham CA
Compton SM
Rasche DP
Mazuski RJ
McDonough JS
Unsinger J
Korman AJ
Green JM
Hotchkiss RS; Pokaż więcej
Źródło :: Critical care (London, England) [Crit Care] 2013 May 11; Vol. 17 (3), pp. R85. Date of Electronic Publication: 2013 May 11.
Typ publikacji :: Journal Article
MeSH Terms :: Antibodies/*therapeutic use
B7-H1 Antigen/*antagonists & inhibitors
CTLA-4 Antigen/*antagonists & inhibitors
Fungemia/*immunology
Fungemia/*therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Animals ; B7-H1 Antigen/immunology ; CTLA-4 Antigen/immunology ; Candidiasis/immunology ; Candidiasis/therapy ; Disease Models, Animal ; Genes, MHC Class I ; HLA-DR Antigens/biosynthesis ; Immunocompromised Host ; Interferon-gamma/biosynthesis ; Male ; Mice, Inbred C57BL ; Programmed Cell Death 1 Receptor/immunology ; Survival Analysis
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 27 27.

Tytuł :: A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection.
Autorzy :: Gardiner D; Bristol-Myers Squibb, Pennington, New Jersey, USA. />Lalezari J
Lawitz E
DiMicco M
Ghalib R
Reddy KR
Chang KM
Sulkowski M
Marro SO
Anderson J
He B
Kansra V
McPhee F
Wind-Rotolo M
Grasela D
Selby M
Korman AJ
Lowy I; Pokaż więcej
Źródło :: PloS one [PLoS One] 2013 May 22; Vol. 8 (5), pp. e63818. Date of Electronic Publication: 2013 May 22 (Print Publication: 2013).
Typ publikacji :: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :: Antibodies, Monoclonal/*therapeutic use
Antiviral Agents/*therapeutic use
Hepacivirus/*drug effects
Hepatitis C, Chronic/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Adult ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/pharmacokinetics ; Antiviral Agents/adverse effects ; Double-Blind Method ; Female ; Half-Life ; Hepacivirus/genetics ; Humans ; Interferon-alpha/therapeutic use ; Male ; Middle Aged ; Nivolumab ; Programmed Cell Death 1 Receptor/metabolism ; RNA, Viral/genetics ; Viral Load/drug effects ; Viral Load/genetics
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 28 28.

Tytuł :: Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Autorzy :: Selby MJ; Authors' Affiliation: Bristol-Myers Squibb Company, Redwood City, California.
Engelhardt JJ
Quigley M
Henning KA
Chen T
Srinivasan M
Korman AJ; Pokaż więcej
Źródło :: Cancer immunology research [Cancer Immunol Res] 2013 Jul; Vol. 1 (1), pp. 32-42. Date of Electronic Publication: 2013 Apr 07.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Antibodies, Monoclonal/*pharmacology
CTLA-4 Antigen/*immunology
Colonic Neoplasms/*therapy
Immunoglobulin G/*immunology
Immunoglobulin G/*pharmacology
T-Lymphocytes, Regulatory/*immunology
Animals ; Antibodies, Monoclonal/immunology ; CHO Cells ; Colonic Neoplasms/immunology ; Cricetulus ; Disease Models, Animal ; Female ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Random Allocation
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 29 29.

Tytuł :: Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
Autorzy :: Wolchok JD; Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA. />Hodi FS
Weber JS
Allison JP
Urba WJ
Robert C
O'Day SJ
Hoos A
Humphrey R
Berman DM
Lonberg N
Korman AJ; Pokaż więcej
Źródło :: Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2013 Jul; Vol. 1291, pp. 1-13. Date of Electronic Publication: 2013 Jun 17.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Antibodies, Monoclonal/*therapeutic use
Antineoplastic Agents/*therapeutic use
Melanoma/*drug therapy
Skin Neoplasms/*drug therapy
Animals ; Antibodies, Monoclonal/immunology ; Antineoplastic Agents/immunology ; Clinical Trials as Topic/methods ; Humans ; Immunotherapy/methods ; Ipilimumab ; Melanoma/immunology ; Melanoma/mortality ; Skin Neoplasms/immunology ; Skin Neoplasms/mortality ; Survival Rate/trends ; Treatment Outcome
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 30 30.

Tytuł :: Nivolumab plus ipilimumab in advanced melanoma.
Autorzy :: Wolchok JD; Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. />Kluger H
Callahan MK
Postow MA
Rizvi NA
Lesokhin AM
Segal NH
Ariyan CE
Gordon RA
Reed K
Burke MM
Caldwell A
Kronenberg SA
Agunwamba BU
Zhang X
Lowy I
Inzunza HD
Feely W
Horak CE
Hong Q
Korman AJ
Wigginton JM
Gupta A
Sznol M; Pokaż więcej
Źródło :: The New England journal of medicine [N Engl J Med] 2013 Jul 11; Vol. 369 (2), pp. 122-33. Date of Electronic Publication: 2013 Jun 02.
Typ publikacji :: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :: Antibodies, Monoclonal/*administration & dosage
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Agents/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
CTLA-4 Antigen/*antagonists & inhibitors
Melanoma/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Skin Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; CTLA-4 Antigen/immunology ; Female ; Humans ; Infusions, Intravenous ; Ipilimumab ; Male ; Melanoma/pathology ; Middle Aged ; Neoplasm Staging ; Nivolumab ; Skin Neoplasms/pathology ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 31 31.

Tytuł :: In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
Autorzy :: Wang C; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Thudium KB; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Han M; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Wang XT; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Huang H; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Feingersh D; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Garcia C; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Wu Y; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Kuhne M; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Srinivasan M; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Singh S; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Wong S; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Garner N; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Leblanc H; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Bunch RT; Bristol-Myers Squibb Company, Mount Vernon, Indiana; and.
Blanset D; Medarex, Princeton, New Jersey.
Selby MJ; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California;
Korman AJ; Biologics Discovery California, Bristol-Myers Squibb Company, Redwood City, California; alan.korman@bms.com.; Pokaż więcej
Źródło :: Cancer immunology research [Cancer Immunol Res] 2014 Sep; Vol. 2 (9), pp. 846-56. Date of Electronic Publication: 2014 May 28.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Antibodies, Monoclonal/*immunology
Lymphocyte Activation/*immunology
Lymphocytes, Tumor-Infiltrating/*immunology
Programmed Cell Death 1 Receptor/*immunology
Animals ; Antibodies, Monoclonal/biosynthesis ; Antigen-Presenting Cells/immunology ; Cell Line, Tumor ; Female ; Humans ; Immunotherapy ; Macaca fascicularis ; Male ; Mice ; Mice, Transgenic ; Neoplasms/therapy ; Nivolumab ; Toxicity Tests ; Tumor Microenvironment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 32 32.

Tytuł :: Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Autorzy :: Gubin MM; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Zhang X; Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Schuster H; Department of Immunology, Institute of Cell Biology, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany.
Caron E; Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland.
Ward JP; 1] Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA [2] Department of Medicine, Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Noguchi T; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Ivanova Y; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Hundal J; The Genome Institute, Washington University School of Medicine, 4444 Forest Park Avenue, St Louis, Missouri 63108, USA.
Arthur CD; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Krebber WJ; ISA Therapeutics B.V., 2333 CH Leiden, The Netherlands.
Mulder GE; ISA Therapeutics B.V., 2333 CH Leiden, The Netherlands.
Toebes M; Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Vesely MD; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Lam SS; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Korman AJ; Bristol-Myers Squibb, 700 Bay Road, Redwood City, California 94063, USA.
Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Sharpe AH; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts 02115, USA.
Pearce EL; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Schumacher TN; Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Aebersold R; 1] Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland [2] Faculty of Science, University of Zurich, Zurich, 8093 Zurich, Switzerland.
Rammensee HG; Department of Immunology, Institute of Cell Biology, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany.
Melief CJ; 1] ISA Therapeutics B.V., 2333 CH Leiden, The Netherlands [2] Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333ZA Leiden, The Netherlands.
Mardis ER; 1] The Genome Institute, Washington University School of Medicine, 4444 Forest Park Avenue, St Louis, Missouri 63108, USA [2] Department of Genetics, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Gillanders WE; Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Artyomov MN; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
Schreiber RD; Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.; Pokaż więcej
Źródło :: Nature [Nature] 2014 Nov 27; Vol. 515 (7528), pp. 577-81.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :: Immunotherapy*
Antibodies, Monoclonal/*therapeutic use
Antigens, Neoplasm/*genetics
Antigens, Neoplasm/*immunology
CD8-Positive T-Lymphocytes/*immunology
Cancer Vaccines/*therapeutic use
Cell Cycle Checkpoints/*immunology
Sarcoma/*therapy
Animals ; Epitopes/genetics ; Male ; Mice ; Sarcoma/immunology ; Vaccines, Synthetic/therapeutic use
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 33 33.

Tytuł :: Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Autorzy :: Hannani D; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Université Paris Sud-XI, Faculté de Médecine, Le Kremlin Bicêtre, France.
Vétizou M; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Université Paris Sud-XI, Faculté de Médecine, Le Kremlin Bicêtre, France.
Enot D; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U848, Villejuif, France [3] Metabolomics Platform, Institut Gustave Roussy, Villejuif, France.
Rusakiewicz S; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.
Chaput N; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.
Klatzmann D; 1] INSERM, Unité Mixte de Recherche_S959, I, Paris, France [2] Assistance-Publique Hopitaux de Paris, Hôpital Pitié-Salpêtrière, Biotherapy, Paris, France.
Desbois M; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.
Jacquelot N; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Université Paris Sud-XI, Faculté de Médecine, Le Kremlin Bicêtre, France.
Vimond N; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.
Chouaib S; INSERM U753, Villejuif, France.
Mateus C; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] Department of Medical Oncology, IGR, Villejuif, France.
Allison JP; Department of Immunology, MD Anderson Cancer Center, Houston, TX, USA.
Ribas A; University of California Los Angeles, Los Angeles, CA, USA.
Wolchok JD; Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Yuan J; Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Wong P; Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Postow M; Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Mackiewicz A; 1] Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, Poznan, Poland [2] Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
Mackiewicz J; 1] Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, Poznan, Poland [2] Chair of Medical Biotechnology, Poznan University of Medical Sciences, Poznan, Poland.
Schadendorff D; Department of Dermatology, University Hospital Essen, Germany.
Jaeger D; National Center for Tumor Diseases, University Hospital, Heidelberg, Germany.
Zörnig I
Hassel J
Korman AJ; Bristol-Myers Squibb, Redwood City, CA, USA.
Bahjat K; Earle A Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA.
Maio M; Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.
Calabro L; Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.
Teng MW; 1] QIMR Berghofer Medical Research Institute, Herston, 4006, Queensland, Australia [2] School of Medicine, The University of Queensland, Herston, QLD 4006, Queensland, Australia.
Smyth MJ; 1] QIMR Berghofer Medical Research Institute, Herston, 4006, Queensland, Australia [2] School of Medicine, The University of Queensland, Herston, QLD 4006, Queensland, Australia.
Eggermont A; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] INSERM U981, Villejuif, France.
Robert C; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Department of Medical Oncology, IGR, Villejuif, France [4] INSERM U981, Villejuif, France.
Kroemer G; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U848, Villejuif, France [3] Metabolomics Platform, Institut Gustave Roussy, Villejuif, France [4] Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U 1138, Paris, France [5] Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France [6] Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Zitvogel L; 1] Gustave Roussy Cancer Campus, Villejuif, France [2] INSERM U1015, Villejuif, France [3] Université Paris Sud-XI, Faculté de Médecine, Le Kremlin Bicêtre, France [4] Department of Medical Oncology, IGR, Villejuif, France.; Pokaż więcej
Źródło :: Cell research [Cell Res] 2015 Feb; Vol. 25 (2), pp. 208-24. Date of Electronic Publication: 2015 Jan 13.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: CTLA-4 Antigen/*metabolism
Interleukin-2 Receptor alpha Subunit/*blood
Melanoma/*pathology
Receptors, Interleukin-2/*metabolism
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Animals ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/metabolism ; CTLA-4 Antigen/immunology ; Cohort Studies ; Disease Models, Animal ; Female ; Humans ; Immunotherapy ; Interleukin-2 Receptor alpha Subunit/immunology ; Ipilimumab ; Male ; Melanoma/mortality ; Melanoma/therapy ; Mice ; Mice, Inbred C57BL ; Middle Aged ; Receptors, Interleukin-2/genetics ; Receptors, Interleukin-2/immunology ; Recombinant Proteins/biosynthesis ; Recombinant Proteins/genetics ; Recombinant Proteins/pharmacology ; T-Lymphocytes, Regulatory/immunology ; Up-Regulation/drug effects ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 34 34.

Tytuł :: Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Autorzy :: Hannani D
Vétizou M
Enot D
Rusakiewicz S
Chaput N
Klatzmann D
Desbois M
Jacquelot N
Vimond N
Chouaib S
Mateus C
Allison JP
Ribas A
Wolchok JD
Yuan J
Wong P
Postow M
Mackiewicz A
Mackiewicz J
Schadendorff D
Jaeger D
Korman AJ
Bahjat K
Maio M
Calabro L
Teng MW
Smyth MJ
Eggermont A
Robert C
Kroemer G
Zitvogel L; Pokaż więcej
Źródło :: Cell research [Cell Res] 2015 Mar; Vol. 25 (3), pp. 399-400.
Typ publikacji :: Published Erratum

Szczegóły

Skocz do pozycji: 35 35.

Tytuł :: The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience.
Autorzy :: Berman D; Bristol-Myers Squibb, Research and Development Division, United States.
Korman A; Bristol-Myers Squibb, Research and Development Division, United States.
Peck R; Bristol-Myers Squibb, Research and Development Division, United States.
Feltquate D; Bristol-Myers Squibb, Research and Development Division, United States.
Lonberg N; Bristol-Myers Squibb, Research and Development Division, United States.
Canetta R; Bristol-Myers Squibb, Research and Development Division, United States. Electronic address: .; Pokaż więcej
Źródło :: Pharmacology & therapeutics [Pharmacol Ther] 2015 Apr; Vol. 148, pp. 132-53. Date of Electronic Publication: 2014 Dec 01.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Antibodies, Monoclonal/*therapeutic use
Immunologic Factors/*therapeutic use
Neoplasms/*drug therapy
Animals ; Antibodies, Monoclonal/adverse effects ; Humans ; Immunologic Factors/adverse effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 36 36.

Tytuł :: TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Autorzy :: Chauvin JM
Pagliano O
Fourcade J
Sun Z
Wang H
Sander C
Kirkwood JM
Chen TH
Maurer M
Korman AJ
Zarour HM; Pokaż więcej
Źródło :: The Journal of clinical investigation [J Clin Invest] 2015 May; Vol. 125 (5), pp. 2046-58. Date of Electronic Publication: 2015 Apr 13.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :: Antigens, Neoplasm/*immunology
CD8-Positive T-Lymphocytes/*immunology
Lymphocytes, Tumor-Infiltrating/*immunology
Melanoma/*immunology
Neoplasm Proteins/*physiology
Programmed Cell Death 1 Receptor/*physiology
Receptors, Immunologic/*physiology
Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/pharmacology ; Antigen-Presenting Cells/immunology ; Antigen-Presenting Cells/metabolism ; Antigens, Differentiation, T-Lymphocyte/biosynthesis ; Antigens, Differentiation, T-Lymphocyte/genetics ; CD8-Positive T-Lymphocytes/metabolism ; Cell Line, Tumor ; Cytokines/biosynthesis ; Gene Expression Regulation, Neoplastic ; Humans ; Immunologic Memory ; Immunophenotyping ; Interleukin-2 Receptor beta Subunit/biosynthesis ; Interleukin-2 Receptor beta Subunit/genetics ; Lymphocyte Activation ; Lymphocytes, Tumor-Infiltrating/metabolism ; Melanoma/pathology ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasm Proteins/biosynthesis ; Neoplasm Proteins/genetics ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/biosynthesis ; Programmed Cell Death 1 Receptor/genetics ; Receptors, Immunologic/antagonists & inhibitors ; Receptors, Immunologic/biosynthesis ; Receptors, Immunologic/genetics ; Receptors, Virus/biosynthesis ; Receptors, Virus/genetics ; T-Cell Antigen Receptor Specificity ; Up-Regulation
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 37 37.

Tytuł :: Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Autorzy :: Melero I; Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain.
Berman DM; Bristol-Myers Squibb, 3551 Lawrenceville Princeton, New Jersey 08648, USA.
Aznar MA; Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain.
Korman AJ; Bristol-Myers Squibb Biologics Discovery California, 700 Bay Road, Redwood City, California 94063, USA.
Pérez Gracia JL; Centro de Investigación Médica Aplicada (CIMA) and Clínica Universitaria, Avenida Pío XII, 55 E-31008, Universidad de Navarra, Pamplona, Spain.
Haanen J; The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Pokaż więcej
Źródło :: Nature reviews. Cancer [Nat Rev Cancer] 2015 Aug; Vol. 15 (8), pp. 457-72.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Immunotherapy*
Neoplasms/*therapy
Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/metabolism ; Clinical Trials as Topic ; Combined Modality Therapy ; Humans ; Molecular Targeted Therapy ; Neoplasms/immunology ; Tumor Microenvironment/immunology
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 38 38.

Tytuł :: Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.
Autorzy :: Sanmamed MF; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain. Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Rodriguez I; Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Schalper KA; Department of Pathology, Yale School of Medicine, New Haven, Connecticut.
Oñate C; Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Azpilikueta A; Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Rodriguez-Ruiz ME; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain. Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Morales-Kastresana A; Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Labiano S; Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Pérez-Gracia JL; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Martín-Algarra S; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Alfaro C; Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
Mazzolini G; Gene Therapy Laboratory, Department of Medicine, Universidad Austral, Pilar, Argentina.
Sarno F; Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain.
Hidalgo M; Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain. Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Korman AJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California.
Jure-Kunkel M; Bristol-Myers Squibb Company, Princeton, New Jersey.
Melero I; Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain. Centro de investigación médica aplicada (CIMA), Universidad de Navarra, Pamplona, Spain. .; Pokaż więcej
Źródło :: Cancer research [Cancer Res] 2015 Sep 01; Vol. 75 (17), pp. 3466-78. Date of Electronic Publication: 2015 Jun 25.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Colorectal Neoplasms/*immunology
DNA-Binding Proteins/*genetics
Interleukin Receptor Common gamma Subunit/*genetics
Programmed Cell Death 1 Receptor/*biosynthesis
T-Lymphocytes/*drug effects
Tumor Necrosis Factor Receptor Superfamily, Member 9/*biosynthesis
Animals ; Antibodies, Monoclonal/administration & dosage ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; DNA-Binding Proteins/immunology ; Graft vs Host Disease/immunology ; Graft vs Host Disease/pathology ; HT29 Cells ; Humans ; Interleukin Receptor Common gamma Subunit/immunology ; Leukocytes, Mononuclear/immunology ; Lymphocyte Activation/immunology ; Mice ; Nivolumab ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; T-Lymphocytes/pathology ; Tumor Necrosis Factor Receptor Superfamily, Member 9/antagonists & inhibitors ; Tumor Necrosis Factor Receptor Superfamily, Member 9/immunology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 39 39.

Tytuł :: FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.
Autorzy :: Dahan R; Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10065, USA.
Sega E; Bristol-Myers Squibb, Biologics Discovery California, Redwood City, CA 94063, USA.
Engelhardt J; Bristol-Myers Squibb, Biologics Discovery California, Redwood City, CA 94063, USA.
Selby M; Bristol-Myers Squibb, Biologics Discovery California, Redwood City, CA 94063, USA.
Korman AJ; Bristol-Myers Squibb, Biologics Discovery California, Redwood City, CA 94063, USA.
Ravetch JV; Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10065, USA. Electronic address: .; Pokaż więcej
Źródło :: Cancer cell [Cancer Cell] 2015 Sep 14; Vol. 28 (3), pp. 285-95.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Antibodies/*immunology
B7-H1 Antigen/*immunology
Neoplasms/*immunology
Programmed Cell Death 1 Receptor/*immunology
Receptors, IgG/*immunology
Animals ; Cell Line, Tumor ; Ligands ; Mice ; Tumor Microenvironment/immunology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 40 40.

Tytuł :: FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.
Autorzy :: Dahan R
Sega E
Engelhardt J
Selby M
Korman AJ
Ravetch JV; Pokaż więcej
Źródło :: Cancer cell [Cancer Cell] 2015 Oct 12; Vol. 28 (4), pp. 543. Date of Electronic Publication: 2015 Oct 12.
Typ publikacji :: Published Erratum

Szczegóły

Skocz do pozycji: 41 41.

Tytuł :: Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab.
Autorzy :: Koguchi Y; Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon.
Hoen HM; Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon.
Bambina SA; Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon.
Rynning MD; R&D Systems, Minneapolis, Minnesota.
Fuerstenberg RK; R&D Systems, Minneapolis, Minnesota.
Curti BD; Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon.
Urba WJ; Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon.
Milburn C; Bristol-Myers Squibb, Redwood City, California.
Bahjat FR; Bristol-Myers Squibb, Redwood City, California.
Korman AJ; Bristol-Myers Squibb, Redwood City, California.
Bahjat KS; Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon. .; Pokaż więcej
Źródło :: Cancer research [Cancer Res] 2015 Dec 01; Vol. 75 (23), pp. 5084-92.
Typ publikacji :: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :: Antibodies, Monoclonal/*therapeutic use
Chemokine CXCL11/*blood
Histocompatibility Antigens Class I/*blood
Melanoma/*blood
Melanoma/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Cancer Vaccines/therapeutic use ; Female ; Humans ; Ipilimumab ; Kaplan-Meier Estimate ; Male ; Melanoma/immunology ; Melanoma/pathology ; Middle Aged ; Neoplasm Metastasis ; Survival Rate ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 42 42.

Tytuł :: TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection.
Autorzy :: Chew GM; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
Fujita T; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.; Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Webb GM; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Burwitz BJ; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Wu HL; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Reed JS; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Hammond KB; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Clayton KL; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
Ishii N; Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Abdel-Mohsen M; Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Liegler T; Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Mitchell BI; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
Hecht FM; HIV/AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Ostrowski M; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
Shikuma CM; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
Hansen SG; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Maurer M; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America.
Korman AJ; Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America.
Deeks SG; HIV/AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
Sacha JB; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
Ndhlovu LC; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.; Pokaż więcej
Źródło :: PLoS pathogens [PLoS Pathog] 2016 Jan 07; Vol. 12 (1), pp. e1005349. Date of Electronic Publication: 2016 Jan 07 (Print Publication: 2016).
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :: CD4-Positive T-Lymphocytes/*immunology
CD8-Positive T-Lymphocytes/*immunology
HIV Infections/*immunology
Receptors, Immunologic/*immunology
Animals ; B7-H1 Antigen/immunology ; Cell Separation ; DNA, Viral/analysis ; Disease Progression ; Flow Cytometry ; Humans ; Lymphocyte Activation/immunology ; Macaca mulatta ; RNA, Viral/analysis ; Simian Acquired Immunodeficiency Syndrome/immunology
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 43 43.

Tytuł :: The Human Vaccines Project: A roadmap for cancer vaccine development.
Autorzy :: Romero P; Ludwig Cancer Research at University of Lausanne, 1066 Epalinges, Switzerland.
Banchereau J; The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA.
Bhardwaj N; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Cockett M; Bristol-Myers Squibb, Wallingford, CT06492, USA.
Disis ML; University of Washington School of Medicine, Seattle, WA 98109-4714, USA.
Dranoff G; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.
Gilboa E; Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA.
Hammond SA; MedImmune, Gaithersburg, MD 20878, USA.
Hershberg R; Celgene Immuno-Oncology Center of Excellence, 1616 Eastlake Avenue, Suite 500, Seattle, WA 98102, USA.
Korman AJ; Bristol-Myers Squibb, Biologics Discovery California, Redwood City, CA 94063, USA.
Kvistborg P; Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands.
Melief C; ISA Pharmaceuticals & Leiden University Medical Center, 2333 ZA Leiden, Netherlands.
Mellman I; Genentech, San Francisco, CA 94080, USA.
Palucka AK; The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032, USA. Baylor Institute for Immunology Research, Dallas, TX 75204, USA.
Redchenko I; Oxford University, Oxford OX3 7DQ, UK.
Robins H; Adaptive Biotechnologies, Fred Hutchinson Cancer Research Center, Seattle, WA 98102, USA.
Sallusto F; Institute for Research in Biomedicine, Università della Svizzera italiana, 6500 Bellinzona, Switzerland.
Schenkelberg T; West Monument Consulting, 1906 R Street NW Street 11, Washington, DC 20009, USA.
Schoenberger S; Center for Personalized Cancer Immunotherapy, La Jolla Institute for Allergy and Immunology & UCSD Moores Cancer Center, La Jolla, San Diego, CA 92037, USA.
Sosman J; Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA.
Türeci Ö; CI3 Cluster for Individualized Immunotherapy, Kupferbergterasse 17-19, 55131 Mainz, Germany.
Van den Eynde B; Ludwig Institute for Cancer Research, Brussels branch, Brussels, BRU 1200, Belgium. Université Catholique de Louvain, Avenue Hippocrate 10, 1200 Woluwe-Saint-Lambert, Belgium. University of Oxford, Nuffield Department of Medicine, Ludwig Institute for Cancer Research, Old Road Campus Research Building, Oxford OX3 7DQ, UK.
Koff W; International AIDS Vaccines Initiative, 125 Broad Street, 9th Floor, New York, NY 10004, USA.
Coukos G; Ludwig Cancer Research at University of Lausanne, 1066 Epalinges, Switzerland. .; Pokaż więcej
Źródło :: Science translational medicine [Sci Transl Med] 2016 Apr 13; Vol. 8 (334), pp. 334ps9.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :: Cancer Vaccines/*immunology
Antigens, Neoplasm/immunology ; Humans ; Immunologic Memory ; T-Lymphocytes/immunology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 44 44.

Tytuł :: Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.
Autorzy :: Houot R; Department of Hematology, CHU de Rennes , Rennes, France.
Gaulard P; Department of Pathology, Inserm U955, Université Paris-Est, CHU Henri Mondor , Créteil, France.
Schreiber R; Department of Pathology and Immunology, Washington University , St. Louis, MO, USA.
Mellman I; Genentech , South San Francisco, CA, USA.
Lambotte O; Department of Clinical Immunology and Internal Medicine, Hospital Kremlin Bicêtre, Université Paris-Sud , Orsay, France.
Coulie PG; de Duve Institute, Université Catholique de Louvain , Brussels, Belgium.
Fest T; Inserm U917, CHU de Rennes , Rennes, France.
Korman A; Bristol-Myers Squibb , CA, USA.
Levy R; Stanford School of Medicine , Stanford, CA, USA.
Shipp M; Dana-Farber Cancer Institute , Boston, MA, USA.
Tarte K; Inserm U917, CHU de Rennes , Rennes, France.
Kohrt H; Department of Medicine, Stanford School of Medicine , Stanford, CA, USA.
Marabelle A; Gustave Roussy Cancer Campus , Villejuif, France.
Ansell S; Division of Hematology , Mayo Clinic, Rochester, MN, USA.
Watier H; CHRU de Tours, Université François-Rabelais and CNRS, UMR7292 , Tours, France.
van Elsas A; Aduro Biotech Europe , Oss, The Netherlands.
Balakumaran A; Clinical Research-Oncology , Merck & Co , Kenilworth, NJ, USA.
Arce Vargas F; UCL Cancer Institute, University College of London , London, UK.
Quezada SA; UCL Cancer Institute, University College of London , London, UK.
Salles G; Department of Hematology, Université Claude Bernard, Hospices Civils de Lyon , INSERM 1052 , Lyon, France.
Olive D; Inserm UMR 1068, Institut Paoli Calmettes, Aix Marseille Université , Marseille, France.; Pokaż więcej
Źródło :: Oncoimmunology [Oncoimmunology] 2016 May 19; Vol. 5 (7), pp. e1186323. Date of Electronic Publication: 2016 May 19 (Print Publication: 2016).
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 45 45.

Tytuł :: Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
Autorzy :: Dahan R; Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230 York Avenue, New York, NY 10021-6399, USA.
Barnhart BC; Bristol-Myers Squibb, Biologics Discovery California, 700 Bay Road, Redwood City, CA 94063, USA.
Li F; Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230 York Avenue, New York, NY 10021-6399, USA.
Yamniuk AP; Bristol-Myers Squibb, Department of Molecular Discovery Technologies, Princeton, NJ 08543, USA.
Korman AJ; Bristol-Myers Squibb, Biologics Discovery California, 700 Bay Road, Redwood City, CA 94063, USA.
Ravetch JV; Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230 York Avenue, New York, NY 10021-6399, USA. Electronic address: .; Pokaż więcej
Źródło :: Cancer cell [Cancer Cell] 2016 Jun 13; Vol. 29 (6), pp. 820-831. Date of Electronic Publication: 2016 Jun 02.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :: Antibodies, Monoclonal/*administration & dosage
Antibodies, Monoclonal, Humanized/*administration & dosage
CD40 Antigens/*agonists
Neoplasms/*drug therapy
Receptors, IgG/*immunology
Animals ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal, Humanized/immunology ; Cell Line, Tumor ; Humans ; Immunotherapy ; Mice ; Neoplasms/immunology ; Xenograft Model Antitumor Assays
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 46 46.

Tytuł :: In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.
Autorzy :: Morris ZS; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin. .
Guy EI; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Francis DM; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Gressett MM; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Werner LR; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Carmichael LL; Department of Biostatistics and Bioinformatics, University of Wisconsin, Madison, Wisconsin.
Yang RK; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Armstrong EA; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Huang S; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Navid F; Department of Oncology, St. Jude Children's Hospital, Memphis, Tennessee.
Gillies SD; Provenance Biopharmaceuticals, Carlisle, Massachusetts.
Korman A; Bristol Myers Squibb, Redwood, California.
Hank JA; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Rakhmilevich AL; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Harari PM; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Sondel PM; Department of Human Oncology, University of Wisconsin, Madison, Wisconsin. Department of Pediatrics, University of Wisconsin, Madison, Wisconsin. Department of Genetics, University of Wisconsin, Madison, Wisconsin.; Pokaż więcej
Źródło :: Cancer research [Cancer Res] 2016 Jul 01; Vol. 76 (13), pp. 3929-41. Date of Electronic Publication: 2016 May 06.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :: Antibodies, Monoclonal/*pharmacology
CTLA-4 Antigen/*immunology
Interleukin-2/*immunology
Lung Neoplasms/*therapy
Melanoma, Experimental/*therapy
Pancreatic Neoplasms/*therapy
Animals ; Apoptosis/drug effects ; Apoptosis/radiation effects ; Blotting, Western ; Cell Proliferation/drug effects ; Cell Proliferation/radiation effects ; Chemoradiotherapy ; Combined Modality Therapy ; Female ; Humans ; Immunoenzyme Techniques ; Lung Neoplasms/immunology ; Lung Neoplasms/secondary ; Melanoma, Experimental/immunology ; Melanoma, Experimental/pathology ; Mice ; Mice, Inbred C57BL ; Pancreatic Neoplasms/immunology ; Pancreatic Neoplasms/pathology ; T-Lymphocytes/immunology ; Tumor Cells, Cultured ; Vaccination ; X-Rays ; Xenograft Model Antitumor Assays
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 47 47.

Tytuł :: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Autorzy :: Selby MJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Engelhardt JJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Johnston RJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Lu LS; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Han M; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Thudium K; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Yao D; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Quigley M; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Valle J; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Wang C; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Chen B; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Cardarelli PM; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Blanset D; Bristol-Myers Squibb, Redwood City, CA, United States of America.
Korman AJ; Bristol-Myers Squibb, Redwood City, CA, United States of America.; Pokaż więcej
Źródło :: PloS one [PLoS One] 2016 Sep 09; Vol. 11 (9), pp. e0161779. Date of Electronic Publication: 2016 Sep 09 (Print Publication: 2016).
Typ publikacji :: Journal Article
MeSH Terms :: Immunotherapy*
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Melanoma/*drug therapy
Animals ; Antibodies, Monoclonal/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/metabolism ; Cell Line, Tumor ; Cells, Cultured ; Colorectal Neoplasms/metabolism ; Colorectal Neoplasms/therapy ; Combined Modality Therapy ; Disease Models, Animal ; Female ; Humans ; Ipilimumab ; Lymphocytes/immunology ; Lymphocytes/metabolism ; Macaca fascicularis ; Melanoma/metabolism ; Melanoma/therapy ; Mice ; Mice, Inbred C57BL ; Nivolumab ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/metabolism ; T-Lymphocytes, Regulatory/metabolism
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 48 48.

Tytuł :: Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.
Autorzy :: Ngiow SF; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. .; School of Medicine, University of Queensland, Herston, Queensland, Australia.
Young A; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.; School of Medicine, University of Queensland, Herston, Queensland, Australia.
Blake SJ; Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Hill GR; Bone Marrow Transplant Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.; Department of Haematology and Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Butterfield St, Brisbane, Queensland, Australia.
Yagita H; Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan.
Teng MW; School of Medicine, University of Queensland, Herston, Queensland, Australia.; Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Korman AJ; Bristol Myers Squibb Company, Redwood City, California.
Smyth MJ; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia. .; School of Medicine, University of Queensland, Herston, Queensland, Australia.; Pokaż więcej
Źródło :: Cancer research [Cancer Res] 2016 Nov 01; Vol. 76 (21), pp. 6266-6277. Date of Electronic Publication: 2016 Sep 09.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Antibodies, Monoclonal/*therapeutic use
CD40 Antigens/*antagonists & inhibitors
Interleukin-12/*physiology
Neoplasms/*drug therapy
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
T-Lymphocytes/*physiology
Animals ; Interleukin-23/physiology ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Neoplasms/immunology ; T-Lymphocytes, Regulatory/physiology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 49 49.

Tytuł :: Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Autorzy :: Selby MJ
Engelhardt JJ
Johnston RJ
Lu LS
Han M
Thudium K
Yao D
Quigley M
Valle J
Wang C
Chen B
Cardarelli PM
Blanset D
Korman AJ; Pokaż więcej
Źródło :: PloS one [PLoS One] 2016 Nov 18; Vol. 11 (11), pp. e0167251. Date of Electronic Publication: 2016 Nov 18 (Print Publication: 2016).
Typ publikacji :: Published Erratum

Szczegóły Pełny tekst

Skocz do pozycji: 50 50.

Tytuł :: Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
Autorzy :: Noguchi T; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.
Ward JP; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Gubin MM; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.
Arthur CD; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.
Lee SH; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri.
Hundal J; McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri.
Selby MJ; Bristol-Myers Squibb, Redwood City, California.
Graziano RF; Bristol-Myers Squibb, Lawrenceville, New Jersey.
Mardis ER; McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri.; Department of Genetics, Washington University School of Medicine, St. Louis, Missouri.
Korman AJ; Bristol-Myers Squibb, Redwood City, California.
Schreiber RD; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri. .; Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St Louis, Missouri.; Pokaż więcej
Źródło :: Cancer immunology research [Cancer Immunol Res] 2017 Feb; Vol. 5 (2), pp. 106-117. Date of Electronic Publication: 2017 Jan 10.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms :: Gene Expression*
B7-H1 Antigen/*genetics
Neoplasms/*genetics
Neoplasms/*immunology
Tumor Escape/*genetics
Tumor Escape/*immunology
Animals ; Cell Line, Tumor ; Cell Proliferation ; Disease Models, Animal ; Female ; Gene Knockout Techniques ; Genes, MHC Class I/genetics ; Genes, MHC Class I/immunology ; Humans ; Male ; Mice ; Mutation ; Neoplasms/pathology ; Sarcoma/genetics ; Sarcoma/immunology ; Sarcoma/pathology ; Tumor Burden ; Tumor Microenvironment/genetics ; Tumor Microenvironment/immunology
: Czasopismo naukowe

Szczegóły

Wyświetlanie 1-50 z 82

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Korman, Alan"" wg kryterium: Autor

Aktywne filtry:

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język